Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

In this multinational, randomised, treat-to-target trial, patients with T2DM who intended to fast and were on basal, pre- or self-mixed insulin ± oral antidiabetic drugs for ≥90 days were randomised (1:1) to IDegAsp twice daily (BID) or BIAsp 30 BID.

Treatment period included pre-Ramadan treatment initiation (with insulin titration for 8-20 weeks), Ramadan (4 weeks) and post-Ramadan (4 weeks).

How the Study Was Run

In design terms this was a randomized study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Drug Combinations, Fasting, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Aspart and Insulin, Long-Acting.

The authors tagged it with the keywords Biphasic insulin aspart 30, Hypoglycaemia, Insulin degludec/insulin aspart, Ramadan fasting and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized study of Insulin Aspart.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Insulin Aspart compound page, all human trials.